Pomalidomide ( DrugBank: Pomalidomide )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
28	全身性アミロイドーシス	9
51	全身性強皮症	6
85	特発性間質性肺炎	1
227	オスラー病	2
331	特発性多中心性キャッスルマン病	1

28. 全身性アミロイドーシス

臨床試験数 : 267 / 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

diseases per page:

Showing 1 to 9 of 9 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05451771 (ClinicalTrials.gov)	October 26, 2022	6/7/2022	Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis	An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Sy ...	AL Amyloidosis	Drug: Venetoclax Oral Tablet, 200 mg;Device: FISH assay;Drug: Venetoclax Oral Tablet, 400 mg;Drug: D ...	Rajshekhar Chakraborty, MD	Genentech, Inc.	Recruiting	18 Years	N/A	All	53	Phase 1/Phase 2	United States
2	NCT05066607 (ClinicalTrials.gov)	February 11, 2022	24/8/2021	Isatuximab Plus Pomalidomideand Dexamethasone Association for Patients With AL Amyloidosis Not in VG ...	A Phase 2, Open Label, Multicenter, Single-stage Study to Evaluate the Efficacy of Isatuximab Plus P ...	AL Amyloidosis	Drug: Isatuximab	Intergroupe Francophone du Myelome	Sanofi;Bristol-Myers Squibb	Recruiting	18 Years	N/A	All	46	Phase 2	France
3	NCT04270175 (ClinicalTrials.gov)	April 14, 2021	12/2/2020	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pa ...	Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Pa ...	Amyloid;AL Amyloidosis;Refractory AL Amyloidosis	Drug: Daratumumab;Drug: Pomalidomide;Drug: Dexamethasone	Weill Medical College of Cornell University	Janssen Scientific Affairs, LLC	Recruiting	18 Years	N/A	All	21	Phase 2	United States
4	EUCTR2019-001962-13-IT (EUCTR)	13/01/2021	21/10/2020	Daratumumab and Pomalidomide in previously treated patients with AL amyloidosis	A multi-center open label phase II study of daratumumab and pomalidomidein previously treated patien ...	AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System ...	Trade Name: Imnovid Product Name: Pomalidomide Product Code: [Pomalidomide] INN or Proposed INN: pomali ...	FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Italy
5	NCT01807286 (ClinicalTrials.gov)	January 2014	6/3/2013	Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis	A Phase I/II Clinical Trial of PomalidomideWith Melphalan and Dexamethasone in Patients With Newly D ...	Myeloma	Drug: Pomalidomide;Drug: Melphalan;Drug: Dexamethasone;Behavioral: Questionnaires	M.D. Anderson Cancer Center	Celgene	Terminated	18 Years	N/A	Both	3	Phase 1	United States
6	NCT01728259 (ClinicalTrials.gov)	March 2013	13/11/2012	First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD	Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amy ...	Light Chain Deposition Disease;Primary Systemic Amyloidosis	Drug: pomalidomide;Drug: bortezomib;Drug: dexamethasone;Other: Laboratory Biomarker Analysis	Barbara Ann Karmanos Cancer Institute	National Cancer Institute (NCI)	Active, not recruiting	18 Years	N/A	All	36	Phase 1	United States;Canada;New Zealand
7	NCT01570387 (ClinicalTrials.gov)	June 2012	27/2/2012	A Phase I/II Trial of Pomalidomideand Dexamethasone in Subjects With Previously-Treated AL Amyloidos ...	A Phase I/II Trial of Pomalidomideand Dexamethasone in Subjects With Previously-Treated AL Amyloidos ...	AL Amyloidosis	Drug: Pomalidomide;Drug: Dexamethasone	Boston Medical Center	Celgene Corporation	Completed	18 Years	N/A	All	27	Phase 1/Phase 2	United States
8	EUCTR2011-001787-22-IT (EUCTR)	02/05/2012	12/01/2012	Treatment with pomalidomide and dexamethasone for previously treated patients with AL amyloidosis.	An open-label, phase II study of Pomalidomideand Dexamethasone (PDex) for previously treated patient ...	Previously treated AL amyloidosis MedDRA version: 14.1;Level: PT;Classification code 10002022;Term: ...	Product Name: pomalidomide Product Code: CC-4047 INN or Proposed INN: Pomalidomide INN or Proposed INN: ...	OSPEDALE POLICLINICO S. MATTEO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Italy
9	NCT01510613 (ClinicalTrials.gov)	February 2012	11/1/2012	Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis	An Open-label, Phase II Study of Pomalidomideand Dexamethasone (PDex) for Previously Treated Patient ...	Primary Amyloidosis of Light Chain Type	Drug: Pomalidomide and Dexamethasone	IRCCS Policlinico S. Matteo	NULL	Completed	18 Years	N/A	All	28	Phase 2	Italy

First Previous1Next Last

先頭へ

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01559129 (ClinicalTrials.gov)	August 9, 2012	19/3/2012	Study of Pomalidomide(CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics ...	A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Ev ...	Scleroderma, Systemic;Sclerosis, Systemic;Systemic Scleroderma;Systemic Sclerosis;Interstitial Lung ...	Drug: Pomalidomide (CC-4047);Drug: Placebo	Celgene	NULL	Terminated	18 Years	80 Years	All	23	Phase 2	United States;Australia;France;Germany;Italy;Poland;Russian Federation;Spain;Switzerland;United King ...
2	EUCTR2010-023047-15-PL (EUCTR)	17/07/2012	14/05/2012	A study to see if pomalidomideis safe and works to treat patients with sclerosis affecting the skin ...	A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Eval ...	systemic sclerosis associated with interstitial lung disease MedDRA version: 16.0;Level: LLT;Classif ...	Product Name: Pomalidomide Product Code: CC-4047 INN or Proposed INN: Pomalidomide	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 2	France;United States;Spain;Poland;Australia;Russian Federation;Germany;Italy;United Kingdom;Switzerl ...
3	EUCTR2010-023047-15-IT (EUCTR)	20/03/2012	28/12/2011	A study to see if pomalidomideis safe and works to treat patients with sclerosis affecting the skin ...	A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Eval ...	Diffuse cutaneous systemic sclerosis with interstitial lung disease MedDRA version: 14.1;Level: LLT; ...	Product Name: Pomalidomide Product Code: CC-4047 INN or Proposed INN: Pomalidomide Other descriptive na ...	CELGENE CORPORATION	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 2	United States;Poland;Spain;Australia;Germany;United Kingdom;Italy
4	EUCTR2010-023047-15-DE (EUCTR)	15/03/2012	08/12/2011	A study to see if pomalidomideis safe and works to treat patients with sclerosis affecting the skin ...	A Phase 2 Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evalu ...	systemic sclerosis associated with interstitial lung disease MedDRA version: 16.1;Level: LLT;Classif ...	Trade Name: Imnovid 1 mg hard capsules INN or Proposed INN: Pomalidomide	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 2	France;United States;Poland;Spain;Australia;Russian Federation;Germany;Italy;United Kingdom;Switzerl ...
5	EUCTR2010-023047-15-GB (EUCTR)	08/03/2012	15/12/2011	A study to see if pomalidomideis safe and works to treat patients with sclerosis affecting the skin ...	A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Eval ...	systemic sclerosis associated with interstitial lung disease MedDRA version: 17.0;Level: LLT;Classif ...	Trade Name: Imnovid 1 mg hard capsules INN or Proposed INN: Pomalidomide	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	88	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	France;United States;Poland;Spain;Australia;Russian Federation;Germany;Italy;Switzerland;United King ...
6	EUCTR2010-023047-15-ES (EUCTR)	02/03/2012	19/01/2012	A study to see if pomalidomideis safe and works to treat patients with sclerosis affecting the skin ...	A Phase 2, Proof-of-Concept, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Eval ...	diffuse cutaneous systemic sclerosis associated with interstitial lung disease MedDRA version: 14.1; ...	Product Name: Pomalidomida Product Code: CC-4047 INN or Proposed INN: Pomalidomida	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 2	France;United States;Poland;Spain;Australia;Germany;Italy;United Kingdom;Switzerland;Sweden

First Previous1Next Last

先頭へ

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01135199 (ClinicalTrials.gov)	June 2010	28/5/2010	Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis	Safety and Efficacy of Pomalidomidein the Treatment of Refractory Cough in Patients With Idiopathic ...	Pulmonary Fibrosis	Drug: pomalidomide (CC-4047	Stanford University	Celgene Corporation	Withdrawn	18 Years	N/A	Both	0	Phase 2	United States

First Previous1Next Last

227. オスラー病

臨床試験数 : 56 / 薬物数 : 72 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03910244 (ClinicalTrials.gov)	October 17, 2019	8/4/2019	Pomalidomide for the Treatment of Bleeding in HHT	Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia	Telangiectasia, Hereditary Hemorrhagic	Drug: Pomalidomide Oral Product;Drug: Placebo oral capsule	The Cleveland Clinic	RTI International	Recruiting	18 Years	N/A	All	159	Phase 2	United States
2	NCT02287558 (ClinicalTrials.gov)	January 27, 2015	6/11/2014	Pomalidomidein Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a P ...	A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomidein Patients With Bleedin ...	Hereditary Hemorrhagic Telangiectasia;Idiopathic Vascular Ectasia	Drug: Pomalidomide	The Cleveland Clinic	NULL	Completed	18 Years	N/A	All	9	Phase 1	United States

First Previous1Next Last

331. 特発性多中心性キャッスルマン病

臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02228512 (ClinicalTrials.gov)	August 15, 2014	27/8/2014	Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas	Phase I/II Study of PomalidomideCombined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lym ...	Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;Primary Effusion Lymph ...	Drug: Pomalidomide;Drug: Rituximab;Drug: Prednisone;Drug: Etoposide;Drug: Doxorubicin;Drug: Vincrist ...	National Cancer Institute (NCI)	NULL	Withdrawn	18 Years	99 Years	All	0	Phase 1/Phase 2	United States

First Previous1Next Last

先頭へ